Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin and Cladribine in Recurrent/Refractory AML (POG 9720)
NCT00003178Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 1998
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of idarubicin and cladribine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Children's Oncology Group. Primary endpoint: Event Free Survival. Started Mar 1998; status: completed.
02
Drugs
idarubicincladribine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003178.